EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Current management options for rosacea: clear skin is our reality

Olga Yu. Olisova, E. M. Anpilogova

Russian Journal of Skin and Venereal Diseases · 15.10.2020 · 23 (5) · 324-333

DOI: 10.17816/dv49867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Russian Journal of Skin and Venereal Diseases, online erschienen am 15.10.2020. Verfasst von Olga Yu. Olisova und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Treatment of rosacea makes enough difficulties. Review of current etiology, pathogenesis and social burden of rosacea are presented, as well as results of international studies on efficacy of brimonidine gel (Mirvaso Derm) and ivermectin creme (Soolantra) usage in erytemato-teleangiectatic and papulopustular rosacea. AIMS: To evaluate efficacy and safety of topical ivermectin and brimonidine for the treatment of rosacea. MATERIALS AND METODS: Results of our own experience of using these drugs in 87 rosacea patients are presented. Depending on the subtype and severity of the disease, patients with erythematotelangiectatic subtype rosacea were treated with Mirvaso Derm gel (59%), Soolantra cream, and tacrolimus ointment (41%); doxycycline 0.10.2 g twice a day and Soolantra cream (29%); and minocycline 0.050.1 g a day and Soolantra cream (37%). Moreover, patients with papulopustular subtype rosacea were treated with the following combined therapy: doxycycline/minocycline + Mirvaso Derm gel + Soolantra cream (34%). Regardless of the severity of the process, all patients received Cetaphil Pro for redness prone skin (Cetaphil Redness Control line until 2018) as daily skin care products. The mean duration time of therapy for antibiotics was 1.52 month and topical therapy had a relatively longer duration time of therapy: from 8 to 24 months for Mirvaso Derm and 3 to 10 months for Soolantra. RESULTS: After the therapy 43 and 55% of patients with papulopustular rosacea achieved Investigator Global Assessment (IGA) scores of 0 (clear) and 1 (almost clear), respectively; and 41% and 50% of patients with erythemato-telangiectatic rosacea achieved IGA scores 0 and 1, respectively. During the 1-year follow-up clear and almost clear skin (IGA = 01) remained in 87% of patients with papulopustular subtype rosacea and 79% of patients with erythemato-telangiectatic subtype rosacea. CONCLUSION: Thus, based on the results, Mirvaso Derm gel and Soolantra creme have demonstrated to be very effective and safe options for rosacea treatment.

Zitieren

APA

Olisova, O. Y., & Anpilogova, E. M. (2020). Current management options for rosacea: clear skin is our reality. Russian Journal of Skin and Venereal Diseases, 23(5), 324-333. https://doi.org/10.17816/dv49867

Vancouver

Olisova OY, Anpilogova EM. Current management options for rosacea: clear skin is our reality. Russian Journal of Skin and Venereal Diseases. 2020;23(5):324-333. doi:10.17816/dv49867

BibTeX
@article{Olisova2020,
  author = {Olisova, Olga Yu. and Anpilogova, E. M.},
  title = {Current management options for rosacea: clear skin is our reality},
  journal = {Russian Journal of Skin and Venereal Diseases},
  year = {2020},
  volume = {23},
  number = {5},
  pages = {324--333},
  doi = {10.17816/dv49867}
}
Kostenlos starten →